Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Preliminary absorbed dose evaluation of two novel 153Sm bone-seeking agents for radiotherapy of bone metastases: comparison with 153Sm-EDTMP

Preliminary absorbed dose evaluation of two novel 153Sm bone-seeking agents for radiotherapy of... AbstractAimThe amount of energy deposited on any organ by ionising radiation termed absorbed dose, plays an important role in evaluating the risks associated with the administration of radiopharmaceuticals. In this research work, the absorbed dose received by human organs for 153Sm-TTHMP and 153Sm-PDTMP was evaluated based on biodistribution studies on the Syrian rats.Materials and methods153Sm-TTHMP and 153Sm-PDTMP were successfully prepared with radiochemical purity of higher than 99%. The biodistribution of the complexes was investigated within the Syrian rats up to 48 hours post injection. The human absorbed dose of the complexes was estimated by the radiation dose assessment resource method.ResultsThe highest absorbed dose for 153Sm-TTHMP and 153Sm-PDTMP was observed in the trabecular bone with 1·085 and 1·826 mGy/MBq, respectively. The bone to other critical organ dose ratio for 153Sm-PDTMP is significantly greater than 153Sm-TTHMP. Also, the bone/red marrow dose ratio for these complexes is comparable with this ratio for 153Sm-EDTMP, as the most clinically used Sm-153 bone pain palliative radiopharmaceutical.FindingsAccording to the considerable bone absorbed dose against the insignificant absorbed dose of non-target organs, these complexes can be used as potential bone pain palliative agents in clinical applications. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Radiotherapy in Practice Cambridge University Press

Preliminary absorbed dose evaluation of two novel 153Sm bone-seeking agents for radiotherapy of bone metastases: comparison with 153Sm-EDTMP

Journal of Radiotherapy in Practice , Volume 14 (3): 8 – May 8, 2015
Download PDF
8 pages

Loading next page...
 
/lp/cambridge-university-press/preliminary-absorbed-dose-evaluation-of-two-novel-153sm-bone-seeking-BjJ0p2siO9

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Cambridge University Press
Copyright
© Cambridge University Press 2015 
ISSN
1467-1131
eISSN
1460-3969
DOI
10.1017/S1460396915000199
Publisher site
See Article on Publisher Site

Abstract

AbstractAimThe amount of energy deposited on any organ by ionising radiation termed absorbed dose, plays an important role in evaluating the risks associated with the administration of radiopharmaceuticals. In this research work, the absorbed dose received by human organs for 153Sm-TTHMP and 153Sm-PDTMP was evaluated based on biodistribution studies on the Syrian rats.Materials and methods153Sm-TTHMP and 153Sm-PDTMP were successfully prepared with radiochemical purity of higher than 99%. The biodistribution of the complexes was investigated within the Syrian rats up to 48 hours post injection. The human absorbed dose of the complexes was estimated by the radiation dose assessment resource method.ResultsThe highest absorbed dose for 153Sm-TTHMP and 153Sm-PDTMP was observed in the trabecular bone with 1·085 and 1·826 mGy/MBq, respectively. The bone to other critical organ dose ratio for 153Sm-PDTMP is significantly greater than 153Sm-TTHMP. Also, the bone/red marrow dose ratio for these complexes is comparable with this ratio for 153Sm-EDTMP, as the most clinically used Sm-153 bone pain palliative radiopharmaceutical.FindingsAccording to the considerable bone absorbed dose against the insignificant absorbed dose of non-target organs, these complexes can be used as potential bone pain palliative agents in clinical applications.

Journal

Journal of Radiotherapy in Practice – Cambridge University Press

Published: May 8, 2015

Keywords: internal dosimetry; PDTMP; RADAR method; Sm-153; TTHMP

References

  • Therapy of metastatic bone pain
  • Radiopharmaceutical therapy for palliation of bone pain from osseous metastases
  • Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention
  • Samarium-153-EDTMP biodistribution and dosimetry estimation
  • Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions
  • Influence of trans-l,2-diaminocyclohexane structure and mixed carboxylic/phosphonic group combinationson samarium-153 chelation capacity and stability
  • Radiopharmaceutical therapy for palliation of bone pain from osseous metastases
  • Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker
  • Production, quality control and biological evaluation of 153Sm-TTHMP as a possible bone palliation agent
  • Radiation dosimetry in nuclear medicine
  • Physical models and dose factors for use in internal dose assessment
  • Preliminary dosimetric evaluation of (166)Ho-TTHMP for human based on biodistribution data in rats
  • Internal dosimetry primer
  • Samarium-153 EDTMP therapy of disseminated skeletal metastasis